Multidisciplinary Association for Psychedelic Studies

Overview

The Multidisciplinary Association for Psychedelic Studies (MAPS) is presented in the source as the organization that built an authorized clinical-research program around MDMA-assisted psychotherapy for severe PTSD.

Current Profile

In the episode’s June 2023 frame, MAPS coordinates or supports clinical groups in the United States, Canada, and elsewhere to compare psychotherapy plus MDMA with psychotherapy plus placebo. The source emphasizes preparation, paired therapists, monitored drug sessions, and follow-up integration rather than recreational access or stand-alone dosing. It also portrays MAPS as seeking legal clinical pathways while avoiding a general recreational-legalization message.

Key Characteristics

• Develops authorized clinical research on MDMA-assisted psychotherapy.
• Uses structured preparation, monitored sessions, and integration around drug administration.
• Focuses the discussed trials on severe PTSD and associated functional burden.
• Operates through a multi-site clinical network described as international.
• Is portrayed as pursuing bounded clinical use rather than recreational legalization.

Evidence

• Research program - The Science of MDMA & Its Therapeutic Uses: Benefits & Risks describes MAPS obtaining authorization for controlled PTSD trials.
• Protocol structure - The Science of MDMA & Its Therapeutic Uses: Benefits & Risks describes preparation, MDMA-or-placebo sessions, paired therapists, and follow-up therapy.
• Institutional stance - The Science of MDMA & Its Therapeutic Uses: Benefits & Risks says MAPS tried to keep the work within legal and clinical boundaries.

Qualifications

This page records the organization’s role as described in a June 2023 episode. It does not establish current organizational structure, approval status, legal access, protocol availability, or the final regulatory interpretation of the trials.

What Changed

• Created a source-bounded profile of MAPS’s MDMA-assisted PTSD research role.

Relationships

• MDMA - investigational compound at the center of the discussed program.
• MDMA-Assisted PTSD Therapy - treatment model tested in the described trials.
• Psychedelic Clinical Supervision Boundary - clinical, legal, and evidence boundary governing the work.
• Medical Risk Management - general framework for participant selection, monitoring, and adverse-risk control.